Lipoglycopeptide antibiotic

This page covers all Lipoglycopeptide antibiotic drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting D-Ala-D-Ala peptidoglycan precursors, Bacterial peptidoglycan (D-Ala-D-Ala), Bacterial peptidoglycan precursors (D-Ala-D-Ala) and lipid II.

Targets

D-Ala-D-Ala peptidoglycan precursors · Bacterial peptidoglycan (D-Ala-D-Ala) · Bacterial peptidoglycan precursors (D-Ala-D-Ala) and lipid II · Lipid II

Marketed (3)

• Dalbavancin via Intravenous Administration · University of Colorado, Denver · Infectious Disease
  Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
• Dalbavancin via Intraperitoneal Administration · University of Colorado, Denver · Infectious Disease
  Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
• Oritavancin Injection · University of Pennsylvania · Infectious Disease
  Oritavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to peptidoglycan precursors and disrupting cross-linking.

Phase 3 pipeline (3)

• IV Dalbavancin · Durata Therapeutics Inc., an affiliate of Allergan plc · Infectious Disease
  Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
• Dalbavancin administration · Assistance Publique - Hôpitaux de Paris · Infectious Disease
  Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
• Single-Dose IV Oritavancin Diphosphate · Melinta Therapeutics, Inc. · Infectious Diseases
  Oritavancin diphosphate is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria.